Strategies to enhance ADCC often involve Fc region modifications to improve CD16 binding and NK cell activation.The tumor-associated expression of NKG2DLs was exploited by developing an Fc-optimized NKG2D-Ig fusion protein (NKG2D-ADCC) to trigger NK cell ADCC against ovarian cancer cells. The gene discussed is KLRK1; the disease is ovarian carcinoma.